Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) went up by 6.70% from its latest closing price compared to the recent 1-year high of $39.78. The company’s stock price has collected 8.07% of gains in the last five trading sessions. The Wall Street Journal reported on 09/30/22 that Amylyx Prices Newly Approved ALS Drug at $12,500 a Month
Is It Worth Investing in Amylyx Pharmaceuticals Inc. (NASDAQ :AMLX) Right Now?
Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Amylyx Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $48.80, which is $8.36 above the current price. AMLX currently public float of 49.98M and currently shorts hold a 11.28% ratio of that float. Today, the average trading volume of AMLX was 775.45K shares.
AMLX’s Market Performance
AMLX stocks went up by 8.07% for the week, with a monthly jump of 13.76% and a quarterly performance of 11.47%, while its annual performance rate touched 99.31%. The volatility ratio for the week stands at 8.23% while the volatility levels for the past 30 days are set at 6.16% for Amylyx Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 11.79% for AMLX stocks with a simple moving average of 60.54% for the last 200 days.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with BofA Securities repeating the rating for AMLX by listing it as a “Buy.” The predicted price for AMLX in the upcoming period, according to BofA Securities is $50 based on the research report published on January 05th of the current year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $21. The rating they have provided for AMLX stocks is “Buy” according to the report published on May 25th, 2022.
Goldman gave a rating of “Neutral” to AMLX, setting the target price at $10 in the report published on April 01st of the previous year.
AMLX Trading at 11.59% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.67% of gains for the given period.
Volatility was left at 6.16%, however, over the last 30 days, the volatility rate increased by 8.23%, as shares surge +11.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.84% upper at present.
During the last 5 trading sessions, AMLX rose by +8.07%, which changed the moving average for the period of 200-days by +193.90% in comparison to the 20-day moving average, which settled at $36.39. In addition, Amylyx Pharmaceuticals Inc. saw 9.45% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AMLX starting from VIKING GLOBAL INVESTORS LP, who sale 700,000 shares at the price of $30.23 back on Sep 09. After this action, VIKING GLOBAL INVESTORS LP now owns 1,850,940 shares of Amylyx Pharmaceuticals Inc., valued at $21,159,753 using the latest closing price.
VIKING GLOBAL INVESTORS LP, the 10% Owner of Amylyx Pharmaceuticals Inc., sale 700,000 shares at $29.37 during a trade that took place back on Sep 08, which means that VIKING GLOBAL INVESTORS LP is holding 2,075,470 shares at $20,559,887 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -29013.33 for the present operating margin
- +81.75 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc. stands at -30852.98. Equity return is now at value -172.50, with -93.60 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.84.